Avila Therapeutics
Avila Therapeutics designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics operates as a subsidiary of Celgene Corporation.
Industries
Nr. of Employees
small (1-50)
Avila Therapeutics
Products
ELIQUIS (apixaban)
A medication used to reduce the risk of stroke and blood clots in people with atrial fibrillation.
REVLIMID (lenalidomide)
A drug for treating multiple myeloma and other blood cancers.
OPDIVO (nivolumab)
An immunotherapy treatment for various types of cancer.
POMALYST/Imnovid (pomalidomide)
A medication for multiple myeloma patients who have received at least two prior therapies.
ORENCIA (abatacept)
A treatment for rheumatoid arthritis and other autoimmune diseases.
SPRYCEL (dasatinib)
A drug used to treat chronic myeloid leukemia and acute lymphoblastic leukemia.
ELIQUIS (apixaban)
A medication used to reduce the risk of stroke and blood clots in people with atrial fibrillation.
REVLIMID (lenalidomide)
A drug for treating multiple myeloma and other blood cancers.
OPDIVO (nivolumab)
An immunotherapy treatment for various types of cancer.
POMALYST/Imnovid (pomalidomide)
A medication for multiple myeloma patients who have received at least two prior therapies.
ORENCIA (abatacept)
A treatment for rheumatoid arthritis and other autoimmune diseases.
SPRYCEL (dasatinib)
A drug used to treat chronic myeloid leukemia and acute lymphoblastic leukemia.